The Q3 beat on EPS and OI is driven by one-time cost savings (lower litigation, completed IIA amortization) rather than revenue recovery. The key catalyst to watch is whether the new China distributor and Orion Medical can sustain replacement revenue in Q4 to hit the ~7% full-year decline target. The stock has rallied 32% YTD, pricing in a turnaround that has not yet materialized in top-line results.
Price Chart
Executive Summary
UTMD reported Q3 2026 revenue of $8.6M (-12.1% YoY) and GAAP EPS of $0.876 (+6.8% YoY). While revenue continued to decline due to lost customers and weaker Filshie clip sales, operating income rose 7% YoY as litigation and amortization expenses dropped sharply. Management guided for a full-year 2026 revenue decline of ~7%, an improvement from the 12% YTD decline, citing the Orion Medical acquisition and a new China distributor.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $8,621K vs $9,812K YoY (-12.1%)
- Q3 2026 GAAP diluted EPS $0.876 vs $0.820 YoY (+6.8%)
- Operating income $2,795K vs $2,612K YoY (+7.0%) due to lower litigation and IIA amortization
- 9M 2026 revenue $25,873K vs $29,475K YoY (-12.2%)
- 9M 2026 GAAP EPS $2.537 vs $2.680 YoY (-5.3%)
- Management now projects full-year 2026 revenue decline of ~7%, improved from 12% YTD decline
- Filshie Clip System sales fell 32.7% in Q3 2026 vs Q3 2025
- Orion Medical Supplies Ltd acquired in August 2026 for $5.0M, contributed $619K in Q3 sales
- New China BPM kit distributor generated $195K in Q3 2026 sales
- Balance sheet remains debt-free with $85.2M cash and investments
- Litigation expenses in Q3 2026 were $203K vs $389K in Q3 2025
Financial Impact
Revenue decline of 12.1% YoY in Q3; EPS up 6.8% YoY due to cost savings; full-year guidance narrowed to ~7% decline
Risk Factors
- Revenue still declining 12% YoY with no sign of stabilization in core Filshie and NICU product lines
- Full-year guidance of ~7% decline implies a sharp Q4 improvement that may not materialize
- Litigation expenses may rise again as two cases head to trial in 2027
- New China distributor and biopharma customer ramp slower than expected
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001096906-26-001602 |
| Document: utmd-20261022_8k.htm | 0001096906-26-001602 |
| Document: 0001096906-26-001602-index-headers.html | 0001096906-26-001602 |
| Document: 0001096906-26-001602-index.html | 0001096906-26-001602 |
| Document: 0001096906-26-001602.txt | 0001096906-26-001602 |
| 8-K Data (Synthetic) | 0001096906-26-001602 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 22, 2026 4d ago | 8-K | $75.06 | awaiting T+20 | — | $73.31 (−2.34%) |
Oct 5, 2026 22d ago | SC TO-I/A | $73.31 | awaiting T+20 | — | $73.31 (−0.01%) |
Sep 25, 2026 4w ago | SC TO-C | $74.18 $74.23 | ▲ +0.07% | ▲ +1.54% | $73.31 (−1.18%) |
Sep 24, 2026 4w ago | SC TO-C | $74.18 $74.23 | ▲ +0.07% | ▲ +1.54% | $73.31 (−1.18%) |
Sep 23, 2026 4w ago | SC TO-I | $74.75 $75.06 | ▲ +0.41% | ▲ +0.83% | $73.31 (−1.93%) |
Aug 31, 2026 8w ago | 8-K | $71.13 $74.95 | ▲ +5.37% | ▲ +5.56% | $73.31 (+3.06%) |
Jul 23, 2026 13w ago | 8-K | $64.18 $71.42 | ▼ −11.28% | ▼ −7.97% | $73.31 (−14.22%) |
Apr 23, 2026 26w ago | 8-K | $67.87 $64.17 | ▲ +5.45% | ▲ +10.09% | $73.31 (−8.01%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers